MEDXF Medexus Pharmaceuticals Inc Forecast, Technical & Fundamental Analysis

MEDXF sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for MEDXF moved below the 200-day moving average on November 20, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDXF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MEDXF broke above its upper Bollinger Band on December 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MEDXF entered a downward trend on December 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 19, 2025. You may want to consider a long position or call options on MEDXF as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MEDXF just turned positive on November 24, 2025. Looking at past instances where MEDXF's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

MEDXF moved above its 50-day moving average on December 22, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDXF advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MEDXF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.249) is normal, around the industry mean (21.577). P/E Ratio (202.000) is within average values for comparable stocks, (74.473). MEDXF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.981). MEDXF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.589) is also within normal values, averaging (64.586).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MEDXF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.